2.250USD+2.27%Mkt Cap: 8.95M USDP/E: —Last update: 2026-05-26
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap8.95M USD
Enterprise Value6.93M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-14.50M USD
Revenue/Share—
Last Price2.250 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.15
PEG5.03
EV/EBITDA-0.48
EV/Revenue—
P/S—
P/B3.22
EPS (TTM)-4.52
EPS (Forward)-1.87
52W Range
2.0800% of range41.22
52W High41.22 USD
52W Low2.080 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-205.26%
ROA-117.96%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.90M USD
CapEx (TTM)280.57K USD
FCF Margin—
FCF Yield—
Net Debt-3.88M USD
Net Debt/EBITDA0.27
Balance Sheet
Debt/Equity0.14
Current Ratio1.59
Quick Ratio1.15
Book Value/Sh0.6680 USD
Cash/Share0.9530 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split115:100
Split DateAug 7, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)17.60 USD
Target Range10.00 USD – 25.00 USD
# Analysts5
Ownership
Shares Out.4.20M
Float4.55M
Insiders0.61%
Institutions11.99%
Short Interest
Short Ratio4.7d
Short % Float3.95%
Short % Out.3.92%
Shares Short156.24K
Short (prev mo.)186.89K
Technical
SMA 502.842 (-20.8%)
SMA 2004.038 (-44.3%)
Beta2.03
S&P 52W Chg28.31%
Avg Vol (30d)39.87K
Avg Vol (10d)40.38K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—